Bottle Label 4 mg (71610 0420 60)
Doxazosin
Product Images NDC 71610-420
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Chemical Structure (Doxazosin 01)
Table 3 (Doxazosin 02)
This appears to be a table showing the results of several studies involving the use of doxazosin for treating benign prostatic hyperplasia (BPH). The studies involved titration to either a maximum dose or a fixed dose, with placebo and different doses of doxazosin being compared based on factors such as maximum flow rate and symptom score. Some results are statistically significant compared to placebo. The text also includes some notes on questionnaire ranges and changes to endpoint.*
Figure 1 (Doxazosin 03)
This is a table or chart displaying the mean change in total symptom score and maximum urinary flow rate (in mL/sec) over the course of several weeks of treatment. There is a comparison made between treatment with doxazosin up to a maximum of 8mg and a placebo. There are also specific statistical comparisons made between the treatment and baseline conditions.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
